This utility model relates to a ready-to-use premixed injectable preparation, preferably multiple-dose vial or single-dose ampoule, for treating viral diseases, especially Dengue fever, influenza and HIV/AIDS. A 1-ml ready-to-use premixed preparation comprises preferably about 5 mg to about 40 mg of procaine hydrochloride and preferably about 1 mg to about 4 mg of dexamethasone sodium phosphate as active ingredients, and pharmaceutically acceptable amounts of pharmaceutical excipients and q.s. sterile water. The preparation is pre-packed and pre-sealed in a sterile pharmaceutically acceptable container for commercial sale.
